- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04942028
Exposure Therapy vs. Standardized Education for Distress Related to Somatic Symptoms (SOMEX1)
Randomized Controlled Trial of Internet-delivered Exposure-based Treatment vs. Standardized Education for Distress Related to Somatic Symptoms in Primary Care
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Approximately one fifth of primary care patients seek care for symptoms that cannot readily be given a medical explanation. In addition, primary care is tasked with offering care for prevalent chronic diseases such as asthma and diabetes where somatic symptoms often lead to distress and pervasive behavioral changes. Though a concern with somatic symptoms can be fully warranted, helpful, and transient, it can also be persistent and lead to much unnecessary suffering. Existing treatments commonly yield insufficient effects on medically unexplained symptoms.
Psychological factors - in particular the preoccupation with symptoms - have been found to affect the perception and intensity of a large number of physical symptoms, both with and without a clear medical genesis. In pain, it has for example been found that fear and the preoccupation with symptoms can have a more substantial predictive value for chronicity than pain itself. In general, in individuals who suffer from clinically significant symptom preoccupation, behaviors intended to evaluate symptoms, seek information about symptoms, or avoid discomfort have been found to often contribute to worsened function and increased symptom burden in the long term.
This makes exposure, where the patient willingly and systematically approaches stimuli that give rise to unwanted symptoms or discomfort while refraining from acting on symptoms, a logical intervention. There are several examples where exposure-based treatment has been found to be efficacious when protocols were written to suit a particular group of patients where distress associated with somatic symptoms is common, e.g., a particular functional somatic syndrome in terms of fibromyalgia and irritable bowel syndrome, or a chronic somatic condition such as asthma or atrial fibrillation. Typically, effects on symptoms and the preoccupation with symptoms have been large, and there is evidence to suggests that a reduction in somatic symptom burden may have been mediated by a reduction in symptom preoccupation or behaviors that serve to reduce distress in the short term.
Generalist primary care clinics typically do not have the resources necessary for administering specific psychological treatments for a large number specific functional somatic syndromes or chronic somatic conditions. The investigators suspect that a more general treatment protocol that can be tailored to suit a wide spectrum of physical symptoms could dramatically improve access to exposure-based treatment for patients with distress related to somatic symptoms. This may be particularly true if treatment can be delivered via the internet, which requires less therapist time but often results in similar effects as face-to-face treatment.
The investigators recently completed a feasibility trial at Karolinska Institutet, Sweden (NCT04511286), where the investigators found that an internet-delivered flexible exposure-based treatment for individuals with high levels of symptom preoccupation regardless of somatic symptom domain (N=33; e.g., functional gastrointestinal symptoms, atrial fibrillation, migraine) can be delivered with high treatment adherence, adequate client satisfaction, large and lasting improvement in self-reported somatic symptoms and symptom preoccupation, and no serious adverse events. It is thus motivated to evaluate this treatment format further.
In further evaluating the flexible exposure-based treatment approach for patients with distress related to somatic symptoms it is imperative to conduct a randomized controlled trial versus an informative control condition, focusing on effects on somatic symptoms and symptom preoccupation. It is also important to evaluate if the treatment can be effective in a routine clinical setting and when patients are referred via a clinician such as a general practitioner. In this trial, the investigators aim to evaluate if flexible internet-delivered exposure-based treatment is more effective than an internet-delivered standardized routine care education program for patients with distress related to somatic symptoms in primary care.
- Primary research question:
Compared to the control condition, does flexible internet-delivered exposure-based treatment lead to a larger average improvement in self-rated somatic symptom burden as assessed using the Patient Health Questionnaire 15 (PHQ-15)? Hypothesis: Yes.
- Key secondary research questions:
Compared to the control condition, does flexible internet-delivered exposure-based treatment lead to a larger average improvement in symptom preoccupation, psychiatric symptom burden, and functional impairment? Hypothesis: Yes.
In flexible internet-delivered exposure-based treatment, are effects typically maintained up to 12 months after treatment? Hypothesis: Yes.
Is flexible internet-delivered exposure-based treatment cost-effective compared to the control condition? Hypothesis: Yes.
Is the controlled effect of the flexible exposure-based treatment on self-rated somatic symptoms moderated by baseline symptoms and preoccupation? Hypothesis: Yes.
Is the effect of the flexible exposure-based treatment on self-rated somatic symptom burden mediated by a reduction in symptom preoccupation? Hypothesis: Yes.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Erland Axelsson, PhD
- Phone Number: +46 0706171039
- Email: erland.axelsson@ki.se
Study Locations
-
-
-
Stockholm, Sweden, 11763
- Liljeholmen academic primary care clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- (i) Either much bothered by at least one somatic symptom (2 points on at least one item of the PHQ-15) or at least a moderate overall somatic symptom burden (PHQ-15 sum ≥10), with (ii) recurrent distress related to somatic symptoms ≥4 months
- Interested in completing an intense psychological treatment with the aim of reducing distress associated with physical symptoms
- Adult (≥18 years old)
- Living in Stockholm County
- Can read and write in Swedish
- Complete baseline assessment
Exclusion Criteria:
- Symptoms best explained by, or clinical picture dominated by, severe health anxiety or a non-somatoform psychiatric disorder such as depression, panic disorder, primary insomnia, a chronic stress disorder, or an acute stress disorder
- Severe psychiatric condition or suicidal ideation
- Clear medical risk in taking part in exposure-based treatment (e.g., pregnancy) or somatic condition (e.g., recent cancer diagnosis), or treatment for somatic condition (e.g., recent chemotherapy), makes treatment unfeasible
- Continuous psychotropic medication (antidepressants, anticonvulsants, mood-stabilizers, antipsychotics) not stable in past 4 weeks, or not expected to remain stable over the main phase of the trial
- Severe alcohol or substance use disorder likely to interfere with treatment
- Planned absence for more than 1 week during the intended main phase
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Internet-delivered exposure-based treatment
10 weeks of therapist-guided exposure-based treatment delivered via the Internet.
|
Systematic confrontation with stimuli associated with symptom-related distress, to achieve therapeutic changes in cognitions or behavior
|
Active Comparator: Internet-delivered standardized education and prolonged assessment
10 weeks of therapist-guided intervention based on prolonged assessment and routine care educational material delivered via the Internet.
|
Standardized routine care education for individuals suffering from distress related to somatic symptoms, primarily focusing on healthy lifestyle behaviors such as sleep, diet, and exercise
Patients are encouraged to keep a rudimentary symptom diary to track if and how their symptoms interact with mood and lifestyle behaviors
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient Health Questionnaire-15 (PHQ-15)
Time Frame: Change over the main phase, as modelled using data from all 11 assessments from the baseline assessment to the primary endpoint (≤45 days after treatment). Secondary analyses incorporate 6- and 12-months follow-up assessments.
|
Theoretical range: 0-30.
A higher score indicates a higher subjective somatic symptom burden.
|
Change over the main phase, as modelled using data from all 11 assessments from the baseline assessment to the primary endpoint (≤45 days after treatment). Secondary analyses incorporate 6- and 12-months follow-up assessments.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Somatic Symptom Disorder-B Criteria Scale (SSD-12)
Time Frame: Change over the main phase, as modelled using data from all 11 assessments from the baseline assessment to the primary endpoint (≤45 days after treatment). Additional analyses incorporate 6- and 12-months follow-up assessments.
|
Theoretical range: 0-48.
A higher score indicates higher degree of preoccupation with symptoms.
|
Change over the main phase, as modelled using data from all 11 assessments from the baseline assessment to the primary endpoint (≤45 days after treatment). Additional analyses incorporate 6- and 12-months follow-up assessments.
|
Symptom Preoccupation Scale (preliminary scale)
Time Frame: Change over the main phase, as modelled using data from all 11 assessments from the baseline assessment to the primary endpoint (≤45 days after treatment). Additional analyses incorporate 6- and 12-months follow-up assessments.
|
Under development.
A higher score indicates higher degree of preoccupation with symptoms.
|
Change over the main phase, as modelled using data from all 11 assessments from the baseline assessment to the primary endpoint (≤45 days after treatment). Additional analyses incorporate 6- and 12-months follow-up assessments.
|
GAD-7
Time Frame: Change over the main phase, as modelled using data from the baseline assessment and primary endpoint (≤45 days after treatment). Additional analyses incorporate 6- and 12-months follow-up assessments.
|
Theoretical range: 0-21.
A higher score indicates more general anxiety.
|
Change over the main phase, as modelled using data from the baseline assessment and primary endpoint (≤45 days after treatment). Additional analyses incorporate 6- and 12-months follow-up assessments.
|
Patient Health Questionnaire (PHQ-9)
Time Frame: Change over the main phase, as modelled using data from the baseline assessment and primary endpoint (≤45 days after treatment). Additional analyses incorporate 6- and 12-months follow-up assessments.
|
Theoretical range: 0-27.
A higher score indicates more symptoms of depression.
|
Change over the main phase, as modelled using data from the baseline assessment and primary endpoint (≤45 days after treatment). Additional analyses incorporate 6- and 12-months follow-up assessments.
|
12-item WHO Disability Assessment Schedule 2.0 (WHODAS 2.0)
Time Frame: Change over the main phase, as modelled using data from the baseline assessment and primary endpoint (≤45 days after treatment). Additional analyses incorporate 6- and 12-months follow-up assessments.
|
Theoretical range: 0-100.
A higher score indicates more disability.
|
Change over the main phase, as modelled using data from the baseline assessment and primary endpoint (≤45 days after treatment). Additional analyses incorporate 6- and 12-months follow-up assessments.
|
14-item Health Anxiety Inventory (HAI-14)
Time Frame: Screening only
|
Theoretical range: 0-42.
A higher score indicates more health anxiety.
|
Screening only
|
Alcohol Use Disorders Identification Test (AUDIT)
Time Frame: Screening only
|
Theoretical range: 0-40.
A higher score indicates more problematic alcohol use.
|
Screening only
|
Drug Use Disorders Identification Test (DUDIT)
Time Frame: Screening only
|
Theoretical range: 0-44.
A higher score indicates more problematic substance use.
|
Screening only
|
Credibility/Expectancy scale (C/E scale)
Time Frame: Week 3 of main phase
|
Theoretical range: 0-50.
A higher score indicates higher credibility/expectancy.
|
Week 3 of main phase
|
Working Alliance Inventory (WAI)
Time Frame: Week 3 of main phase
|
Theoretical range: 6-42.
A higher score indicates better relationship with the therapist.
|
Week 3 of main phase
|
Client Satisfaction Questionnaire (CSQ-8)
Time Frame: Primary endpoint assessment (≤45 days after treatment)
|
Theoretical range: 8-32.
A higher score indicates higher satisfaction with treatment.
|
Primary endpoint assessment (≤45 days after treatment)
|
EuroQol 5D (EQ-5D)
Time Frame: Data from the baseline assessment, the primary endpoint, and the 6- and 12-month follow-up are used for health economic analysis focusing on the main phase.
|
Theoretical range: 0-1, i.e., scored as utility for the purpose of calculating quality-adjusted life years for health economic analysis.
A higher utility score indicates a higher health-related quality of life.
|
Data from the baseline assessment, the primary endpoint, and the 6- and 12-month follow-up are used for health economic analysis focusing on the main phase.
|
Trimbos Institute and Institute of Medical Technology Questionnaire for Costs Associated with Psychiatric Illness (TIC-P)
Time Frame: Data from the baseline assessment, the primary endpoint, and the 6- and 12-month follow-up are used for health economic analysis focusing on the main phase.
|
This instrument is scored in terms of resource use for the purpose of calculating societal costs for health economic analysis.
|
Data from the baseline assessment, the primary endpoint, and the 6- and 12-month follow-up are used for health economic analysis focusing on the main phase.
|
Four questions corresponding to presumed components of subjective somatic symptom burden
Time Frame: Measured at screening, baseline assessment, and the primary endpoint
|
These questions concern (1) somatic symptom severity, (2) somatic symptom frequency/duration, (3) distress related to somatic symptoms, and (4) the impact of somatic symptoms on disability.
Answers are given on visual analogue scales.
|
Measured at screening, baseline assessment, and the primary endpoint
|
Seven questions probing into basic emotions related to somatic symptoms
Time Frame: Measured at screening, baseline assessment, and the primary endpoint
|
Answers are given on visual analogue scales.
|
Measured at screening, baseline assessment, and the primary endpoint
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Erland Axelsson, PhD, Liljeholmen academic primary care clinic, Region Stockholm
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2021-01400
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Medically Unexplained Symptoms
-
Yale UniversityWallace Research FoundationCompleted
-
University of California, Los AngelesActive, not recruiting
-
Karolinska InstitutetCompletedSomatic Symptom DisorderSweden
-
Karolinska InstitutetStockholm UniversityCompletedSomatic Symptom DisorderSweden
-
St. Joseph's Healthcare HamiltonUnknownSomatic Symptom Disorders
-
Radboud University Medical CenterCompletedMedically Unexplained Symptoms | Psychosomatic TherapyNetherlands
-
University Hospital, GrenobleGroupe Hospitalier Mutualiste de GrenobleNot yet recruitingAutoimmune Diseases | Medically Unexplained Symptoms | Hypnosis
-
University of OsloRecruitingMedically Unexplained Symptoms | Sense of CoherenceNorway
-
Philipps University Marburg Medical CenterHarvard Medical School (HMS and HSDM); University of Kaiserslautern-LandauCompletedSomatic Symptom DisorderGermany
-
Shanghai Mental Health CenterNot yet recruiting
Clinical Trials on Exposure
-
Radboud University Medical CenterSint MaartenskliniekCompletedPsoriasis | Psoriasis Vulgaris | Psoriatic Arthritis | Psoriatic NailNetherlands
-
Charite University, Berlin, GermanyThe Federal Office for Radiation Protection, Germany; Seibersdorf Labor GmbHCompleted
-
University of WyomingUnknown
-
University of Missouri-ColumbiaCompletedType 2 DiabetesUnited States
-
Red Maple Trials Inc.Ottawa Allergy Research CorporationCompletedAllergic Rhinitis | Rhinoconjunctivitis | ExposureCanada
-
Emory UniversityCenters for Disease Control and PreventionWithdrawnPost Traumatic Stress Disorder, PTSD
-
Uppsala UniversityRecruiting
-
Jamia Millia IslamiaCouncil of Scientific and Industrial Research, IndiaActive, not recruiting
-
University of OuluUniversity of Texas Southwestern Medical Center; Maastricht University; Finnish...Active, not recruitingType 2 DiabetesFinland
-
University of LouisvilleCompletedAnorexia Nervosa | Bulimia Nervosa | Eating Disorder | ExposureUnited States